AKK PROBIO Becomes the First Gut-Derived Akkermansia muciniphila to Complete FDA NDI Notification

In this episode of Global Economic Press, Alex Brady discusses a significant advancement in the field of probiotics with the announcement from Thankcome Biological Science and Technology Co., Ltd. The company has successfully completed the United States Food and Drug Administration New Dietary Ingredient notification process for its next-generation probiotic strain, Akkermansia muciniphila AKK PROBIO. This milestone marks AKK PROBIO as the first strain of human intestinal origin to achieve this status, enhancing its regulatory position alongside its dual self-affirmed Generally Recognized As Safe certification. The episode explores the implications of this achievement for the future of dietary supplements and gut health, highlighting the strain's potential applications in weight management, gut barrier integrity, metabolic health, and more. Thankcome Biological Science and Technology Co., Ltd., a subsidiary of Perfect Group Corporation, Limited, is at the forefront of microbiome research and innovation. The company's AKK PROBIO strain is supported by extensive scientific research, including 18 granted patents, 13 peer-reviewed publications, and 7 clinical studies. These studies demonstrate significant health benefits, such as improvements in body weight, liver function, and emotional well-being. With its comprehensive regulatory framework and proven clinical results, AKK PROBIO is well-positioned to support global partners in delivering science-backed, compliant Akkermansia solutions to the market. For more information about Thankcome and its groundbreaking work, visit their website at Thankcome Biological Science and Technology Co., Ltd..